AUTHORS
Silpita Paul, PhD, Nitesh D. Sharma, PhD2, Fernando Ponce Garcia3, Igor Fijalkowski, PhD4, Wojciech Ornatowski, PhD5, Brunno Gilberto Santos de Macedo6, Anit Tyagi7, Julie A Reisz Haines, PhD8, Iqbal M Hossain, PhD9, Lalitha Appana10, Ellie Hall11, Harish Kumar, PhD12, Ravi Bhatia, MD13, Shaida Andrabi, PhD14, Panagiotis Ntziachristos, PhD15, Angelo D'Alessandro, PhD16, Nicholas Jones, PhD17, Sravanti Rangaraju, MD18, Ksenia Matlawska-Wasowska, PhD19
AFFILIATIONS
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 Swansea University, Swansea, United Kingdom
4 Ghent University, Ghent, Belgium
5 University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 University of Colorado Anschutz, Aurora, Colorado, United States
8 University of Colorado Anschutz, Aurora, Colorado, United States
9 University of Alabama at Birmingham, Birmingham, Alabama, United States
10 University of Alabama at Birmingham, Birmingham, Alabama, United States
11 University of Alabama at Birmingham, Birmingham, Alabama, United States
12 University of Alabama at Birmingham, Birmingham, Alabama, United States
13 University of Alabama at Birmingham, Birmingham, Alabama, United States
14 University of Alabama at Birmingham, Birmingham, Alabama, United States
15 Ghent University, Ghent, Belgium
16 University of Colorado Anschutz, Aurora, Colorado, United States
17 Swansea University, Swansea, United Kingdom
18 University of Alabama at Birmingham, Birmingham, Alabama, United States
19 University of Alabama at Birmingham, Birmingham, Alabama, United States
ABSTRACT
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has poor outcomes, and responses to BCL-2 inhibition are limited by adaptive survival mechanisms. We hypothesized that the proteasome inhibitor bortezomib (Btz) would potentiate venetoclax (Ven) by increasing oxidative stress and disrupting cellular stress adaptation. Dose-matrix assays across seven T-ALL cell lines demonstrated additive or synergistic cytotoxicity, including Bliss scores of 18 and 12 in PER117 (ETP) and Jurkat (non-ETP) cells, respectively. Ven/Btz also increased apoptosis in primary T-ALL samples (n=13), with no significant difference between ETP-ALL and non-ETP-ALL cases (n=5/group). Strikingly, Ven/Btz induced cytoplasmic reactive oxygen species (ROS) within 1-6 h, preceding mitochondrial ROS (12 h), together with increased lipid peroxidation and decreased GPX4 expression. The antioxidant N-acetylcysteine, pan-caspase inhibitor z-VAD-FMK, and ferroptosis inhibitor ferrostatin-1 each partially rescued cell death, supporting ROS-dependent stress, caspase-mediated apoptosis, and ferroptosis-like lipid peroxidation. Ven/Btz also activated mitochondrial quality-control pathways (FIS1, cleaved OPA1, phospho-DRP1, and PINK1), reduced oxygen consumption, induced acute mitochondrial hyperpolarization, and prevented recovery of mitochondrial mass and membrane potential, indicating persistent mitochondrial dysfunction. We next evaluated Ven/Btz in vivo in a PER117 xenograft and non-ETP PDX. In established leukemia, treatment initiated at 2% circulating blasts prolonged survival and reduced bone marrow (BM) and splenic disease versus either agent alone (n=8/group; P<0.05). Ven-persistent T-ALL cells recovered from treated mice and transplanted into secondary recipients remained responsive to Ven/Btz, which prolonged survival and reduced leukemic burden versus Ven alone (n=8/group; P<0.05). In a low-burden model, treatment initiated after inoculation delayed progression and reduced BM, spleen, liver, and CNS disease at day 28 (n=8/group). To define adaptation to early oxidative stress, we performed quantitative proteomics in PER117 cells after 6 h. Ven/Btz induced a coordinated integrated stress response and lipid-metabolic program, characterized by increased expression of SREBP1, CAVIN1, HERPUD1, DDIT4, and NFE2L1, consistent with ATF4-mediated stress adaptation. Ven/Btz also promoted the proteolytic activation and nuclear accumulation of SREBP1, a master lipogenic transcription factor that drives fatty-acid synthesis and lipid storage. Untargeted lipidomics revealed membrane-phospholipid depletion with triglyceride accumulation, while lipid ontology analysis identified triglycerides, neutral-lipid storage, lipid droplets, and fatty-acid metabolism as dominant signatures. Consistently, Ven/Btz increased neutral-lipid accumulation, suggesting fatty-acid sequestration as triglycerides to buffer oxidative membrane damage. Mechanistically, inhibition of DGAT1, the enzyme that catalyzes the final step of triglyceride synthesis, with T863 reduced neutral lipid accumulation and increased lipid peroxidation, and apoptosis. Similarly, shRNA-mediated SREBP1 depletion enhanced Ven/Btz-induced lipid peroxidation and cell death, while fatostatin and the site-1 protease inhibitor PF-429242 phenocopied SREBP1 loss. Primary adult T-ALL samples stratified by baseline SREBP1 protein expression (n=5/group) showed greater Ven/Btz sensitivity in SREBP1-low than SREBP1-high cases. In SREBP1-high samples, pharmacologic inhibition of SREBP1 or DGAT1 reduced neutral lipids and enhanced lipid peroxidation and apoptosis. High SREBP1 expression was associated with inferior event-free survival (log-rank P=0.039) and enrichment of KMT2A, FBXW7 and USP7 lesions, whereas MLLT10 rearrangements and chromosome 19p lesions were associated with lower SREBP1 (Pölönen et al. 2024 dataset). Consistently, MLLT10-rearranged primary samples (n=3) were more sensitive to Ven/Btz than KMT2A-altered samples (n=3), and SREBP1 or DGAT1 inhibition sensitized the latter. In summary, Ven/Btz is active against T-ALL and triggers an early oxidative and lipid-peroxidative crisis while activating a SREBP1-dependent triglyceride storage program that limits membrane damage. Disrupting this adaptive lipid buffering response enhances Ven/Btz-induced cell death, particularly in less sensitive T-ALL samples, identifying lipid metabolism as a therapeutically actionable vulnerability in high-risk disease.
DISCLOSURES
Nitesh D. Sharma, PhD: No relevant conflicts of interest to declare.